Author: Jesse Landry

The cybersecurity industry doesn’t need another product pretending to be AI because someone placed ChatGPT to a spreadsheet. What it does need is fewer false positives, fewer burned-out analysts, and one less budget line for caffeine-induced SOC burnout. Dropzone AI got the memo. And they didn’t whisper it, they dropped $37M of Series B clarity into the noise. Led by Theory Ventures with returning believers Madrona Ventures, Decibel Ventures, Pioneer Square Labs, and In-Q-Tel Inc., this latest round brings Dropzone AI’s total funding to $57.35M. In just 17 months since Edward X. Wu founded the company, the Seattle-based team has…

Let’s talk about Julius AI, a name that sounds like a Roman general but moves like a backchannel hacker who just reverse-engineered your data stack before you finished your coffee. And trust me, the moves aren’t ceremonial. Julius AI is what happens when someone with real technical chops finally gets fed up watching business folks copy/paste from Excel into dashboards they don’t even trust. Founded by Rahul Sonwalkar in July 2023, this isn’t another “AI but for data” pitch deck. It’s a precision-built platform that lets anyone, not just the SQL-elite, analyze, visualize, and interrogate massive datasets in plain English.…

There’s disruption, and then there’s what BetterRX is doing in hospice pharmacy, rewiring the circuitry of a system so bloated with PBMs and rebate gymnastics it forgot who the medication was actually for. Let’s rewind. Jared Stong, PharmD, wasn’t dreaming up SaaS slides in a co-working space. He was in the trenches, an actual hospice pharmacist watching patients suffer because meds got stuck in middleman limbo. One of those patients? His father-in-law. That wasn’t a product-market fit moment. That was a personal line in the sand. So in 2007, Stong built closed-door pharmacies. Not for scale. For speed. Then in…

The clinical trial game has always been a beautiful mess, fragments of data added to Word docs, standards whispered in committees, and timelines that stretch longer than your average pharma earnings call. But Nurocor? Nurocor saw the mess, studied the chaos, and built the infrastructure to govern it. This isn’t just cleanup. It’s a full protocol power wash, and they’ve been quietly rewriting how R&D gets done, one metadata lineage at a time. Now they’ve locked in a $1 million strategic investment from Simulations Plus (Nasdaq: SLP). And this isn’t some passive check in a quiet room. This is a…

There are biotechs. Then there’s MapLight Therapeutics, a Redwood City-born anomaly that didn’t just show up to play, they showed up to rewire the circuitry. And now, with $372.5 million in fresh Series D fuel, they’re not slowing down, they’re targeting the synapses that legacy pharma keeps ghosting. You want conviction? Look at the names behind this. Christopher A. Kroeger, M.D., MBA, CEO, biotech closer, ex-Biogen, ex-Cardioxyl, a guy who knows how to take a molecule and make it matter. And the science bench? That’s not a bench, that’s a power trio. Karl Deisseroth, M.D., Ph.D., Stanford icon and the…

Do you know E2B? They’re busy building the runtime for the future of work, agentic, autonomous, and anything but idle. On July 28, E2B secured a $21M Series A led by Insight Partners, with Decibel, Sunflower Capital, Kaya VC, and angels like former Docker CEO Scott Johnston leaning in. This isn’t just another round, it’s a bet on the infrastructure that’ll power the next evolution of enterprise AI. If you think agents are just another SaaS trend, you’re already two quarters behind. Founded in March 2023 by Václav “Vasek” Mlejnský (CEO) and Tomáš Valenta (CTO), E2B didn’t come from the…

Sometimes the signal isn’t in what’s seen, it’s in what’s missed. And that’s exactly where Overwatch Imaging has built its empire: the margins of vision, the gaps in attention, the dead zones between human capability and machine precision. Founded in 2016 by Greg Davis, a Stanford-trained NASA sim engineer turned ISR whisperer, Overwatch Imaging didn’t stumble into the edge-AI battlefield. They designed for it. With aerospace in their DNA and autonomy in their crosshairs, they’ve built a platform that doesn’t just watch the world, it interprets it in real time. Their flagship software, Automated Sensor Operator (ASO), is the kind…

There are startups, and then there are operators who build in the dark, skip the panels, and make enterprise tech actually usable for people who don’t sit behind a desk. That’s what makes Xemelgo different, and why Zebra Ventures just cut them into the big leagues with a fresh strategic investment. Founded in a basement by two ex-Hitachi heavyweights, Rich Rogers and Akhila Tadinada were chasing the factories where work orders still live on clipboards and spreadsheets. Rich Rogers, named one of Accenture’s Top 40 IoT leaders, spent over a decade at Hitachi Vantara running product and engineering. Akhila Tadinada,…

In a world still letting tech nibble around the edges of healthcare, Scopio Labs just pushed a $10 million extension into their Series D like a scalpel through red tape, and this one cuts clean. This isn’t another glorified microscope startup waving AI pom-poms. Scopio Labs, founded by Itai Hayut (CEO, applied physics PhD, ex-optics guy who could probably build a telescope out of a stapler) and Erez Na’aman (CTO, deep learning and computational photography savant who sees cell structures like Neo sees the Matrix), has been quietly doing the hard thing: turning hematology’s most manual, analog bottleneck, peripheral blood…

Some biotech startups drop funding news like a sleepy pulse ox, flat, clinical, and barely twitching. Not Plexision. This one hits with the precision of a crossmatch and the timing of a six-hour rejection panel. $365,000 may not sound like Series A swagger to the untrained eye, but this isn’t your average bio-buzzword baby. This is real science, real patients, and real impact. The Richard King Mellon Foundation knows the difference and just made a strategic investment in Plexision’s game-changing diagnostics. Founded by two brothers who could walk into a transplant OR or a boardroom and still leave the room…